Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 10, 2021 07:00 ET
|
Shattuck Labs, Inc.
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – IND filings for...
Shattuck Labs Announces Participation in Upcoming May Conferences
April 30, 2021 17:33 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit
April 28, 2021 16:45 ET
|
Shattuck Labs, Inc.
AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Highlights Preclinical Data for SL-9258 (TIGIT-Fc-LIGHT) in an Acquired Resistance Model and Expanded Preclinical Data from the GADLEN™ Platform at AACR 2021
April 12, 2021 07:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Needham’s 20th Annual Healthcare Conference
April 06, 2021 07:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Promotion of Andrew R. Neill to Chief Financial Officer
March 16, 2021 07:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
March 15, 2021 16:45 ET
|
Shattuck Labs, Inc.
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – Dose-escalation data...
Shattuck Labs to Present Two Posters at the 2021 American Association for Cancer Research (AACR) Annual Meeting
March 11, 2021 08:28 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, March 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
February 23, 2021 18:40 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day
February 12, 2021 09:41 ET
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...